Within the agreed twelve-month timeframe, Qlucore has passed all the milestones set out for the first part of the project. After passing review, the second payment from the EU of approximately EUR 0.5 million can therefore be processed.

During the project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for AML and bladder cancer. The project spans over three years. The aim is to develop tests for use in clinical laboratories. Another focus is, in collaboration with the pharmaceutical industry, to develop solutions for companion diagnostics.

“This EU payment will strengthen Qlucore financially. We are at the forefront of RNA-seq-based modern clinical diagnostics and we will continue to work with the milestones set out for this project,” says Carl-Johan Ivarsson, CEO of Qlucore.
 
Intended customers are clinical laboratories across Europe in the first phase, and the US market in the second phase.